Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia

JAMA. 2021 Mar 2;325(9):830-832. doi: 10.1001/jama.2021.1395.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adolescent
  • Antibodies, Bispecific
  • B-Lymphocytes
  • Child
  • Disease-Free Survival
  • Humans
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Recurrence
  • Young Adult

Substances

  • Antibodies, Bispecific
  • blinatumomab